| Investor | Atlas Venture Fund X, L.P. |
13D/G Filings
This page shows a list of all the recent 13D/G filings made by Atlas Venture Fund X, L.P. . Schedule 13D is commonly referred to as a “beneficial ownership report.” The term "beneficial owner" is defined under SEC rules. It includes any person who directly or indirectly shares voting power or investment power (the power to sell the security).
When a person or group of persons acquires beneficial ownership of more than 5% of a voting class of a company’s equity securities, they are required to file a Schedule 13D within ten days after the purchase. Click the link icon to see the full transaction history.
| Date | Form | Target | Prev Shares |
Current Shares |
Change (Percent) |
Ownership (Percent) |
Change (Percent) |
|
|---|---|---|---|---|---|---|---|---|
| 2026-05-28 | 13D/A | QTTB / Q32 Bio Inc. | 864,261 | 864,261 | ||||
| 2026-05-14 | 13G/A | 0 | ||||||
| 2025-12-17 | 13D/A | IRON / Disc Medicine, Inc. | 1,084,527 | 813,167 | ||||
| 2025-08-15 | 13D/A | IRON / Disc Medicine, Inc. | 1,402,186 | 1,084,527 | ||||
| 2025-07-29 | 13D/A | IMA / ImageneBio, Inc. | 241,800 | |||||
| 2024-11-14 | 13G/A | KYMR / Kymera Therapeutics, Inc. | 4,968,114 | 4,173,216 | ||||
| 2024-10-28 | 13D/A | TECX / Tectonic Therapeutic, Inc. | 67,567 | |||||
| 2024-04-01 | 13D | QTTB / Q32 Bio Inc. | 864,261 | |||||
| 2024-02-09 | 13G/A | GBIO / Generation Bio Co. | 7,111,939 | 7,111,939 | ||||
| 2024-02-09 | 13G/A | KYMR / Kymera Therapeutics, Inc. | 5,066,925 | 4,968,114 | ||||
| 2024-01-25 | 13D/A | IRON / Disc Medicine, Inc. | 1,593,785 | 1,402,186 | ||||
| 2023-09-21 | 13D/A | IRON / Disc Medicine, Inc. | 2,237,303 | 1,593,785 | ||||
| 2023-09-15 | 13D/A | DNTH / Dianthus Therapeutics, Inc. | 186,089 | |||||
| 2023-02-14 | 13D/A | IRON / Disc Medicine, Inc. | 2,237,303 | |||||
| 2023-02-14 | 13G/A | KYMR / Kymera Therapeutics, Inc. | 5,763,012 | 5,066,925 | ||||
| 2022-12-06 | 13D/A | REPL / Replimune Group, Inc. | 2,164,037 | 1,498,635 | ||||
| 2022-09-14 | 13D/A | REPL / Replimune Group, Inc. | 2,524,866 | 2,164,037 | ||||
| 2022-05-05 | 13D/A | MGTA / Magenta Therapeutics Inc | 3,357,340 | 2,977,448 | ||||
| 2022-02-11 | 13G/A | KYMR / Kymera Therapeutics, Inc. | 7,948,982 | 5,763,012 | ||||
| 2022-02-11 | 13D | IKNA / Ikena Oncology, Inc. | 2,901,609 | |||||
| 2022-02-11 | 13G/A | GBIO / Generation Bio Co. | 10,111,939 | 7,111,939 | ||||
| 2021-02-17 | 13D/A | MGTA / Magenta Therapeutics Inc | 4,117,125 | 3,357,340 | ||||
| 2021-02-16 | 13D/A | SPRO / Spero Therapeutics, Inc. | 1,031,160 | |||||
| 2021-02-16 | 13G | GBIO / Generation Bio Co. | 10,111,939 | |||||
| 2021-02-16 | 13D | GMTX / Gemini Therapeutics Inc | 4,015,045 | |||||
| 2021-02-16 | 13G | KYMR / Kymera Therapeutics, Inc. | 7,948,982 | |||||
| 2020-09-17 | 13D/A | REPL / Replimune Group, Inc. | 2,961,473 | 2,524,866 | ||||
| 2020-07-14 | 13D | MGTA / Magenta Therapeutics Inc | 4,117,125 | 4,117,125 | ||||
| 2020-07-07 | 13D/A | REPL / Replimune Group, Inc. | 3,398,080 | 2,961,473 | ||||
| 2020-06-19 | 13D/A | REPL / Replimune Group, Inc. | 3,834,587 | 3,398,080 | ||||
| 2020-02-13 | 13G/A | MGTA / Magenta Therapeutics Inc | 4,843,625 | 4,117,125 | ||||
| 2019-11-25 | 13D | REPL / Replimune Group, Inc. | 4,453,386 | 3,834,587 | ||||
| 2019-07-30 | 13D | AVRO / AVROBIO, Inc. | 47,564,781 | 4,756,478 | ||||
| 2019-02-13 | 13G | AVRO / AVROBIO, Inc. | 4,756,478 | |||||
| 2019-02-13 | 13G | MGTA / Magenta Therapeutics Inc | 4,843,625 | |||||
| 2019-02-13 | 13G | REPL / Replimune Group, Inc. | 4,453,386 | |||||
| 2018-03-14 | 13D | SPRO / Spero Therapeutics, Inc. | 1,031,160 |
